How many insider trades does FilingIQ track for SNDX?

FilingIQ tracks 321 Form 4 insider transactions for SNDX (Syndax Pharmaceuticals Inc), covering filings from Mar 20, 2017 onwards. 0 of those were filed in the last 90 days.

Are SNDX insiders net buyers or net sellers?

Across the full Form 4 history for SNDX, 15 transactions (5%) were open-market purchases and 109 (34%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SNDX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SNDX in?

Syndax Pharmaceuticals Inc (SNDX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.75B.

SNDX insider trading

NasdaqGS Healthcare

Syndax Pharmaceuticals Inc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

321

Last 90 days

Buys / sells

5% / 34%

Market cap

$1.75B

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Company website: syndax.com

SNDX insider activity at a glance

FilingIQ has scored 321 insider transactions for SNDX since Mar 20, 2017. The most recent filing in our index is dated Feb 9, 2026.

Across the full history, 15 open-market purchases and 109 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SNDX insider trades is 63.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SNDX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding SNDX

Frazier Life Sciences Management, L.P.

$94.39M · 5.9% of AUM

STEMPOINT CAPITAL LP

$28.99M · 8.5% of AUM

Sofinnova Investments, Inc.

$23.25M · 1.3% of AUM

Exome Asset Management LLC

$2.89M · 2.1% of AUM

Frequently asked

How many insider trades does FilingIQ track for SNDX?: FilingIQ tracks 321 Form 4 insider transactions for SNDX (Syndax Pharmaceuticals Inc), covering filings from Mar 20, 2017 onwards. 0 of those were filed in the last 90 days.
Are SNDX insiders net buyers or net sellers?: Across the full Form 4 history for SNDX, 15 transactions (5%) were open-market purchases and 109 (34%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SNDX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SNDX in?: Syndax Pharmaceuticals Inc (SNDX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.75B.

Methodology & sources

Every SNDX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.